Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TST 001 companion diagnostic - Transcenta Holding

Next Previous
Drug Profile

TST 001 companion diagnostic - Transcenta Holding

Alternative Names: 124I-18B10; TST-001 companion diagnostic - Transcenta Holding

Latest Information Update: 02 Sep 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Transcenta Holding
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Gastrointestinal cancer

Most Recent Events

  • 29 Aug 2024 TST 001 companion diagnotsic is still in clinical trials for Solid tumours in China
  • 29 Aug 2024 Transcenta Holding receives regulatory clearances from the U.S. Food and Drug Administration (FDA), China Center for Drug Evaluation (CDE) and South Korea Ministry of Food and Drug Safety (MFDS) to initiate phase III TranStar 301 pivotal trial in Adenocarcinoma
  • 28 Jul 2024 No recent reports of development identified for clinical-Phase-Unknown development in Gastrointestinal-cancer(Diagnosis) in China (IV, Infusion)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top